Literature DB >> 6437672

Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

S D Smith, M Shatsky, P S Cohen, R Warnke, M P Link, B E Glader.   

Abstract

Recently, four distinct cell lines were established from patients whose malignancies had been defined by immunological and biochemical markers. Each patient had a distinct subtype of a T-cell cancer, and each possessed elevated adenosine deaminase and reduced nucleoside phosphorylase activity. Cell lines cultured in vitro possessed the same basic immunophenotype and biochemical enzyme activity as the patients' original malignant cells. In a direct comparison of the immunophenotype of the cell lines and the patients' malignant cells, full concordance existed for 48 of 52 paired antibody tests performed. However, when compared to the corresponding patient's sample, each cell line showed some minor changes in antigen expression or enzyme level. Antigen loss, de novo antigen expression, or elevated adenosine deaminase levels occurred in the cell lines, and these changes were stable on repeated analysis. While there was good general concordance between the patient's cancer and the established cell line, minor biological differences in the cell lines may reflect cellular maturation or subpopulation selection in vitro.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437672

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  104 in total

1.  A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo.

Authors:  S M Kao; E D Miller; L Su
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

2.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells.

Authors:  Anne-Marie W Turner; Amanda M Ackley; Michael A Matrone; Kevin V Morris
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

6.  Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

Authors:  L Berthoux; C Péchoux; J L Darlix
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Species-specific diversity among simian immunodeficiency viruses from African green monkeys.

Authors:  J S Allan; M Short; M E Taylor; S Su; V M Hirsch; P R Johnson; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  Quantitative analysis of HIV-1 preintegration complexes.

Authors:  Alan Engelman; Ilker Oztop; Nick Vandegraaff; Nidhanapati K Raghavendra
Journal:  Methods       Date:  2009-02-20       Impact factor: 3.608

9.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.